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Fig 2. Left, Transesophageal echocardiograph of left atrium demonstrating small papilliform lesion on the atrial surface of the mitral 
valve (arrowhead). RightJ Histology of lesion excised from mitral valve. Elastin stain, x25.
has been advocated, although postmortem series suggest that 
fibroelastoma is usually an incidental finding.
TEE is superior to TTE or physical examination for the detec­
tion of potential cardioembolic sources.4-5 As with this case, normal 
TTE with potentially emboligenic abnormalities on TEE has been 
reported.6-7 Limited availability of TEE and the uncertain manage­
ment of many abnormalities demonstrated only by this modality 
prevent its routine use after stroke.
Brief high-intensity signals on TCD are thought to represent 
emboli. Spectral analysis may distinguish air from platelet or fibrin 
thrombi.8 The number of signals correlates with the degree of 
neuropsychological dysfunction evident after cardiopulmonary by­
pass procedures9 and may differentiate lacunar strokes (thought to 
result from small-vessel occlusion) and other stroke types.10 HITS 
on TCD may represent continuing subclinical embolism.
The demonstration of bilateral embolic signals in this case 
contributed to the clinical decision to undertake TEE despite 
normal TTE results. The spectral pattern of the emboli suggested 
solid material, but thrombi could not be distinguished from tumor 
fragments. Difficulties in determining the nature of the embolic 
material impair the clinical usefulness of TCD detection of HITS at 
present. However, this case demonstrates that embolic signal 
monitoring by TCD may be a useful adjunct in the investigation of 
patients with a clinical suspicion of an embolic source and partic­
ularly may prompt TEE if bilateral HITS are observed.
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Evaluation of the Presence of Premature 
Atherosclerosis in Adults With Heterozygosity for 
Cystathionine-j3-Synthase Deficiency
To the Editor:
Premature atherosclerosis is a key clinical feature of homozygous 
homocystinuria, an autosomal recessively inherited condition char­
acterized by hyperhomocysteinemia.1 In homocystinuria, hyperho- 
mocysteinemia is in most cases due to the low activity of cystathi- 
onine-j3-synthase (CS), which catalyzes the conversion of 
homocysteine to cystathionine. In some patients, hyperhomocys­
teinemia is caused by a defect in the remethylation of homocysteine 
to methionine because of a deficiency of methionine synthase or 
methylenetetrahydrofolate reductase. Relatives of patients with 
homozygous homocystinuria who are obligate heterozygotes have 
hyperhomocysteinemia. Since homocysteine may be involved in 
atherogenesis,2 these subjects may be at increased risk for prema­
ture atherosclerosis. Because previous studies on manifestations of 
cardiovascular disease have yielded conflicting results,'1“5 we studied 
the prevalence of carotid and femoral atherosclerosis by measuring 
intima-media thickness (IMT) and ankle-brachial index (ABI) in 
enzymatically proven heterozygous relatives of patients with ho­
mozygous homocystinuria due to CS deficiency.
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Intima-media thickness {mm)
Distribution of intima-media thickness in the group of subjects 
younger than 50 years heterozygous for cystathionine-/3-syn- 
thase deficiency (solid line) and control subjects (dashed line).
Twenty-three subjects (14 parents and 9 siblings) were recruited 
from seven families. Three parents were not available (2 because of 
family circumstances, and 1 refused to participate), and 1 young
«
sibling (10 years) was excluded. Of the remaining 19 members, we 
concentrated on the 13 subjects (5 males and 8 females) younger 
than 50 years of age because the aim was to study premature 
atherosclerosis. Mean age was 33.3 (range, 18 to 50) years. The 
control group consisted of 12 healthy subjects with normal methi­
onine loading test results. Blood pressure, plasma creatinine, and 
fasting plasma lipids were similar in both groups. There were more 
smokers in the control group (9) than in the heterozygote group (2, 
73=.015).
Clinical manifestations of coronary, cerebral, or peripheral ar­
tery disease were evaluated by medical history and documentation, 
Since lens luxation occurs frequently in patients with homozygous 
homocystinuria, the heterozygous relatives were examined ophthal- 
mologically (with fundoscopy and photography).
CS activity was measured in cultured skin fibroblasts by the 
radioisotopic method of Mudd et al6 in assays without and with 
pyridoxal phosphate. Subjects were defined as heterozygotes if CS 
activity was below the lower limit of normal. In vivo homocysteine 
metabolism was assessed in an oral methionine loading test. 
Subjects ingested 100 mg/kg body weight of L-methionine after an 
overnight fast, and blood was sampled before and 6 hours after 
methionine ingestion. Plasma total homocysteine was measured by 
the method of Araki and Sako.7 Test results were abnormal if the 
basal homocysteine level was >16,3 ¿imol/L in women and >18.8 
|umol/L in men and/or if the increase was >42.3 jumol/L after 
loading in both sexes. Plasma concentrations of the cofactors 
pyridoxine, folic acid, and cyanocobalamin were determined before 
loading. In relatives, a low enzyme activity was minimally required 
as proof of heterozygosity. ABI was determined at rest and after 
exercise; ABI <0.94 was considered indicative of atherosclerotic 
changes. IMT was measured in segments of distal common carotid, 
carotid bulb, proximal internal carotid, common femoral, and 
superficial femoral artery from both sides. IMT was defined as the 
average distance between lumen-intima and media-adventitia in­
terfaces of each arterial wall segment.
The IMT measurements (mean±SD) were normally distributed, 
and thus the results of heterozygote and control subjects were 
compared with the Student’s t test. Data for all measured segments 
(0.05-mm contingents) were pooled, and a frequency distribution 
was calculated. Level of significance was .05.
None of the subjects had clinical evidence of cerebral, coronary, 
or peripheral arterial disease. Ocular abnormalities associated with 
homocystinuria were not found. All 13 relatives had low unstimu­
lated and stimulated CS activities and were considered heterozy­
gotes. In 11 of the 13 heterozygous subjects, results of the
methionine loading test were abnormal. (Although the results were 
within the normal range in two subjects from one family, these 
subjects were considered heterozygotes because of low CS activity.) 
Plasma concentrations of cofactors were all within the normal 
range except for one marginally lowered cobalamin value.
One heterozygous subject had a marginally low ABI (0.93) in one 
leg. Doppler measurements did not reveal stenoses in the hetero­
zygote group. The exercise test did not reveal abnormal decreases 
in ABI. Mean IMT values were similar in the heterozygous 
(0.59±0.13 mm; median, 0.58 mm) and control groups (0.59±0.11 
mm; median, 0.58 mm; P —.8), with an almost identical IMT 
frequency distribution (Figure). IMT was also similar for both 
groups for each of the five arterial segments.
The absence of changes in the vascular wall of subjects who have 
been exposed to a presumed atherogenic factor may be explained 
in several ways. First, it may be that the relatives were too young to 
have developed structural vascular changes. In one study, heterozy­
gous subjects with an increased carotid IMT were significantly 
older than subjects with a normal IMT.5 The mean±SD age of the 
patients in the study who showed lower mean ABI and higher 
frequency of Doppler abnormalities in heterozygote subjects com­
pared with control subjects was 46±12 years, indicating that if 
normally distributed there would be the same number of subjects 
older and younger than 46 years. In the study of Malinow et al,H the 
asymptomatic subjects who had an increased IMT with high plasma 
homocysteine levels were between 45 and 64 years of age. How­
ever, patients of comparable or younger age than our subjects with 
other atherogenic conditions, such as insulin-dependent diabetes 
mellitus or familial hypercholesterolemia,9*12 have been shown to 
have a.n increased IMT. Second, although cross-sectional and 
prospective studies have demonstrated that hyperhomocysteinemia 
is associated with an increased risk of premature atherosclerosis, 
these are not heterozygous for CS deficiency, and in addition 
multiple risk factors may be present and interact.13 A high fre­
quency of decreased rate of remethylation with decreased activity 
of the thermolabile fraction of methylene tetrahydrofolate reductase 
has been detected in these patient groups.14 Third, hyperhomocys­
teinemia may affect the coagulation cascade more than the vascular 
wall.15-17 Our results do not support rigorous implementation of 
extensive vascular assessment of subjects who are heterozygous for CS 
deficiency and whose homozygous relatives have symptomatic disease,
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